Log In Get Started
Insider Trading July 2, 2026 04:48 PM

Sionna Therapeutics Director Sells $5.27M in Stock Amid Mixed Analyst Outlook

Peter Thompson's transaction follows a year of significant stock appreciation, yet valuation concerns and upcoming clinical data keep investors cautious.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SION

Peter A. Thompson, a director at Sionna Therapeutics, Inc. (NASDAQ: SION), executed a sale of common stock valued at approximately $5.27 million, according to a report filed on June 30, 2026. The transaction involved the disposal of 115,844 shares at $45.50 per share. While SION shares currently trade at $43.99, the sale comes against a backdrop of a 99.5% stock return over the past year. Despite this impressive performance, analysis suggests the stock may be overvalued relative to its fair value, and the company remains unprofitable with no near-term profitability expected from analysts. The transaction was conducted under a Rule 10b5-1 trading plan, with shares held indirectly through OrbiMed Private Investments VIII, LP. Thompson continues to hold 2,555,877 shares indirectly. Meanwhile, analyst sentiment on SION is divided, with Stifel and Citizens maintaining bullish views on the company's NBD1 data, while Freedom Broker has downgraded the stock to Hold following the completion of enrollment for the SION-719 Phase 2a trial. Investors are closely monitoring upcoming clinical readouts that could impact future trial directions.

Sionna Therapeutics Director Sells $5.27M in Stock Amid Mixed Analyst Outlook
SION
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Peter Thompson, a director at Sionna Therapeutics, sold $5.27 million worth of stock, reducing his indirect holdings but maintaining a significant position of 2,555,877 shares.
  • Analyst sentiment on SION is divided, with Stifel and Citizens maintaining bullish views on the company's NBD1 data, while Freedom Broker has downgraded the stock to Hold following the completion of enrollment for the SION-719 Phase 2a trial.
  • Despite a 99.5% stock return over the past year, Sionna Therapeutics remains unprofitable, and analysts do not expect profitability this year, with the stock considered overvalued relative to its fair value.

Peter A. Thompson, serving as a director at Sionna Therapeutics, Inc. (NASDAQ: SION), has reported the disposal of common stock amounting to roughly $5.27 million. The transaction, which was reported on June 30, 2026, entailed the sale of 115,844 shares at a price of $45.50 per share. This sale occurred as SION shares were currently trading at $43.99, a figure that sits below the price at which the transaction was executed. The move comes in the wake of a remarkable 99.5% return for the stock over the past year, according to InvestingPro analysis. Despite this strong performance, the analysis indicates that the stock is overvalued relative to its Fair Value, positioning it among the highly valued stocks in the market. Sionna Therapeutics, with a market capitalization of $1.88 billion, remains unprofitable, and analysts do not anticipate the company achieving profitability this year.

The securities sold by Thompson were disposed of pursuant to a Rule 10b5-1 trading plan. These shares are held indirectly by OrbiMed Private Investments VIII, LP. Thompson is a member of OrbiMed Advisors LLC, which acts as the managing member of the general partner of OrbiMed Private Investments VIII, LP. OrbiMed Advisors and its general partner have disclaimed beneficial ownership of these securities except to the extent of their pecuniary interest. Following this transaction, Thompson indirectly holds 2,555,877 shares of Sionna Therapeutics common stock.

In recent developments, Sionna Therapeutics has been the subject of several analyst updates. Stifel has maintained its Buy rating for Sionna Therapeutics, raising its price target from $44 to $55, citing confidence in the company's NBD1 data. Citizens has also reiterated a Market Outperform rating with a $63 price target, highlighting the potential of Sionna's NBD1 stabilizers for cystic fibrosis treatment. Conversely, Freedom Broker has downgraded the stock to Hold from Buy, maintaining a $38 price target, after the completion of enrollment for the SION-719 Phase 2a trial. The firm noted that upcoming readouts would address the biological risk associated with the NBD1 stabilizer mechanism.

Stifel's meetings with Sionna executives, including CEO Mike Cloonan, focused on the upcoming phase 2a proof-of-concept readout scheduled for this summer. Investors are closely watching these developments, as the data could influence future trials. The expectations from these firms reflect varied perspectives on Sionna's potential market performance. The stock currently trades at $43.99, with a 1D change of +2.35 (+5.64%), and after hours trading at $44.17, with a 1D change of +0.18 (+0.41%).

Risks

  • The upcoming readouts from the SION-719 Phase 2a trial will address biological risks associated with the NBD1 stabilizer mechanism, which could significantly impact future trial directions and investor sentiment.
  • Sionna Therapeutics remains unprofitable, and analysts do not expect profitability this year, which could lead to continued valuation concerns and market volatility.
  • The stock is currently considered overvalued relative to its fair value, which may pose a risk to investors if the company fails to meet high expectations driven by recent analyst upgrades.

More from Insider Trading

PennyMac Financial Executive Divests Shares Under Pre-Arranged Trading Plan Jul 2, 2026 Calumet Director Daniel Sajkowski Executes Pre-Arranged Sale Amid Volatile Earnings Landscape Jul 2, 2026 Auburn National Bancorporation Director Expands Position Through Dividend Reinvestment Plan Jul 2, 2026 Carvana CFO Jenkins Executes Pre-Arranged Stock Sales and Option Exercises Jul 2, 2026 Verisign Executive Offloads Shares Amid Strong Q1 Performance Jul 2, 2026